INDIGO’s New Family of Assays for Environmental Monitoring and Toxicology Provide a Screening Tool for Endocrine Disrupting Chemicals State College, PA (May 18, 2023) – Today INDIGO Biosciences released a new family of cell-based luciferase reporter assays specifically developed for use in environmental testing applications such as screening samples for endocrine disrupting chemicals. The assaysRead More
INDIGO Biosciences Releases Reporter Assays for Insulin Receptor and Insulin-like Growth Factor 1 Receptor
Two New Assays for Preclinical Research of Cancer, Diabetes, and Cardiovascular Disease State College, PA (17 April 2023) – INDIGO Biosciences announced today the release of two new cell-based reporter assays for the Insulin Receptor, isoform B (INSRb) and Insulin-like Growth Factor 1 Receptor (IGF-1R), both members of the receptor tyrosine kinase (RTK) family. “TheseRead More
INDIGO Biosciences Announces Record Year for 2022
Cell-Based Assay Solutions Provider Books Another Year of Record Growth State College, PA (February 22, 2023) – INDIGO Biosciences, Inc. (INDIGO), best known for its portfolio of cell-based luciferase reporter assays, experienced a record year of growth in 2022, with annual revenue 22% percent higher than 2021. “INDIGO provides exceptional value to the industries weRead More
Human Tropomyosin Receptor Kinase TrkA, TrkB, TrkC Assays Now Available
Assays for Human Tropomyosin Receptor Kinases Developed to Help Identify Inhibitors and Activators of Nerve Growth Factor Receptors State College, PA (January 3, 2023) – INDIGO Biosciences announced today the release of three new cell-based luciferase reporter assays for Human Tropomyosin Receptor Kinases TrkA (NTRK1), TrkB (NTRK2), and TrkC (NTRK3). TrkA, TrkB, and TrkC—also knownRead More